AxoGen(AXGN)
$55.93+0.53 (+0.96%)
AXGN
AxoGen stock drug pipeline
$55.93
At close:+0.53 (+0.96%)
Want to see AXGN full AI Analyst Report?
AxoGen (AXGN) Drug Pipeline
509 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Avance Nerve Graft, Sural Nerve Autograft | Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury, Upper Extremity Nerve Injury | Phase IV | Recruiting | A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction | Jun 15, 2026 | ― |
| Processed Nerve Allograft, Collagen Nerve Cuff | Peripheral Nerve Discontinuities | Phase III | Completed | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair | Mar 04, 2013 | ― |
| Processed Human Nerve Tissue Scaffold | Peripheral Nerve Injury, Prostate Cancer, Radical Prostatectomy, Nerve Reconstruction, Cavernous Nerve Injury | Phase IV | Completed | Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer | Aug 04, 2009 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Avance Nerve Graft, Sural Nerve Autograft | Phase IV | Peripheral Nerve Injury, Peripheral Nerve Discontinuity, Mixed Peripheral Nerve Injury, Motor Peripheral Nerve Injury, Upper Extremity Nerve Injury | Recruiting | A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction | Jun 15, 2026 | ― |
| Processed Nerve Allograft, Collagen Nerve Cuff | Phase III | Peripheral Nerve Discontinuities | Completed | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair | Mar 04, 2013 | ― |
| Processed Human Nerve Tissue Scaffold | Phase IV | Peripheral Nerve Injury, Prostate Cancer, Radical Prostatectomy, Nerve Reconstruction, Cavernous Nerve Injury | Completed | Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer | Aug 04, 2009 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does AxoGen (AXGN) have in its pipeline
AxoGen AXGN is currently developing the following drugs: Avance Nerve Graft, Sural Nerve Autograft, Processed Nerve Allograft, Collagen Nerve Cuff, Processed Human Nerve Tissue Scaffold. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
